Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

Xencor (NASDAQ:XNCR) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other analysts have also recently weighed in on XNCR. Truist Financial cut their price target on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. JPMorgan Chase & Co. upped their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Cantor Fitzgerald raised their price target on shares of Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Thursday. Royal Bank Of Canada boosted their price objective on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Wedbush upped their price objective on shares of Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Xencor has an average rating of “Hold” and an average price target of $24.86.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $20.81 on Friday. The company has a market cap of $1.55 billion, a P/E ratio of -9.59 and a beta of 0.85. The business has a 50-day simple moving average of $15.69 and a two-hundred day simple moving average of $13.38. Xencor has a 52 week low of $6.92 and a 52 week high of $21.96.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. During the same quarter last year, the firm posted ($0.41) EPS. The company’s revenue was up 17.4% compared to the same quarter last year. Equities research analysts anticipate that Xencor will post -2.99 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XNCR. AQR Capital Management LLC acquired a new stake in Xencor during the 1st quarter worth $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Xencor by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 3,692 shares during the period. Goldman Sachs Group Inc. increased its holdings in Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after purchasing an additional 344,088 shares during the period. Creative Planning increased its stake in shares of Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 3,661 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Xencor by 170.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock valued at $2,594,000 after purchasing an additional 208,182 shares in the last quarter.

Xencor News Roundup

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Quarterly results beat expectations: Xencor reported a second-quarter loss of $0.29 per share, narrower than the $0.80–$0.82 consensus estimate and better than the $0.41 loss recorded a year earlier. Revenue reached approximately $51.2 million, well above the roughly $18.9 million analyst forecast and up 17.4% year over year. Xencor Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised valuation expectations: Wedbush increased its price target from $26 to $30 and maintained an “outperform” rating. Cantor Fitzgerald also raised its target from $43 to $44 while keeping an “overweight” rating, signaling substantial potential upside based on their estimates. Analyst Price Target Updates
• Positive Sentiment: RBC Capital reaffirmed its “buy” rating for Xencor, providing additional support for the bullish analyst view following the earnings release. RBC Capital Sticks to Their Buy Rating for Xencor
• Neutral Sentiment: Brokerage consensus remains cautious: Despite several bullish individual ratings, the overall analyst consensus is “hold,” suggesting that expectations for Xencor remain mixed. Xencor Given Consensus Rating of Hold
• Negative Sentiment: Profitability remains a risk: Xencor continues to report net losses, and analysts forecast a full-year loss. The company’s negative margins mean the stock remains dependent on clinical, commercial, and partnership progress to justify its valuation.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.